Bevacizumab for Breast Cancer Hotly Debated

Monday 6 September 2010

The use of bevacizumab (Avastin, Roche) in the treatment of breast cancer has hit the headlines again. Many media outlets in the United Stateshave been discussing the fact that US Food and Drug Administration (FDA) approval for the use of bevacizumab in the treatment of metastatic breast cancer could be revoked.

>> http://www.medscape.com/viewarticle/727239?sssdmh=dm1.633176&src=nldne&uac=152441AJ


Further information

European Oncology Nursing Society
Avenue E. Mounier 83
B-1200 Brussels
Belgium
Tel: +32 (0)2 779 9923
Fax: +32 (0)2 779 9937
eons.secretariat@cancernurse.eu